CIRM Scientific and Medical Research Funding Working Group: Biographical information of candidates nominated to serve as Alternate Scientific Members of the Working Group

1. Amelia Bartholomew, MD

Dr. Amelia Bartholomew is the Chief of the Division of Transplantation Research at the University of Illinois at Chicago and an Associate Professor in the Departments of Surgery and Molecular Genetics. She is also an attending surgeon in General and Transplant Surgery at the University of Illinois Hospital and Clinics. Dr. Bartholomew received her BS and her MD from the Honors Program in Medicine at Northwestern University. She completed her internship and residency in surgery at the University of Illinois in Chicago and Cook County Hospital, becoming an Administrative Chief Resident in Surgery. Thereafter, she was a fellow in multi-organ transplantation at Massachusetts General Hospital.

Dr Bartholomew is a principle investigator for research programs funded by NIAID and BARDA to define the contribution of the manipulated bone marrow microenvironment in the resolution of tissue injury and the initiation of tissue regeneration and repair. This multi-million dollar product development program is anticipated to result in new INDs for the use of parathyroid hormone in stem cell and regenerative medicine therapies. Other lines of investigation include pre-clinical studies on the induction of transplantation tolerance using hematopoietic and mesenchymal stem cell therapeutics, and application of mesenchymal and hematopoietic stem cells in facilitating the success of xenotransplants. Dr. Bartholomew's work in mesenchymal stem cells has been widely cited. Her research efforts have resulted in patents licensed by industry for clinical development. In anticipation of the expertise required to translate of her research studies to clinical trial, she is completing an MS in Public Health from John Hopkins School of Public Health this May.

Dr. Bartholomew is certified by the American Board of Surgery and is a fellow for the American College of Surgeons. She has participated in scientific study sections/review groups for the National Institutes of Health (NIAID, NCI, NHLBI), the American Society of Hematology, the National Kidney Foundation, and the American Society for Transplantation as well as numerous scientific journals.

2. Bruce R. Blazar, MD

Bruce R. Blazar is a Professor of Pediatrics and the Chief of the Pediatric Blood and Marrow Transplantation Program at the University of Minnesota. He holds the Andersen Chair in Transplantation Immunology and is a member of the Academic Health Center's Academy of Excellence in Health Research. Dr. Blazar is also the AHC Assistant Vice President for Clinical and Translational Science Programs and directs the Clinical and Translational Science Institute (CTSI) and the Center for Translational Medicine. He received his BS in biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in 1978. He completed his internship, residency and was Chief Resident in Pediatrics at the University of Minnesota. He was also a Medical Fellow in

Pediatric Hematology-Oncology/Blood and Marrow Transplantation and a Postdoctoral Research Associate in Pediatrics at the University of Minnesota.

Dr. Blazar has directed immunology and stem cell research in preclinical basic, translational, and early phase clinical studies for more than 20 years, with particular emphasis in marrow transplantation immunobiology. Under his direction, the Center for Translational medicine, an integrated component of CTSI, which designed to transform health through clinical translational science and community-University partnerships, brings innovative, early-phase therapies into the clinic.

Dr. Blazar is board certified in Pediatrics and in the Hematology-Oncology subspecialty. He is the principal investigator of several NIH-funded studies focusing on bone marrow transplantation and cancer immunobiology in both preclinical model systems and in the clinic. His contributions to research and his scientific achievement at a national level were recognized by the NHLBI in 1998, when he was honored with an NHLBI MERIT (Method to Extend Research in Time) Award.

3. Scott Burger, MD

Dr. Burger is the principal of Advanced Cell & Gene Therapy. After completing his BS at Tulane University, he received his MD from the University of Pennsylvania School of Medicine. He completed postgraduate training in Laboratory Medicine as well as a clinical fellowship in Transfusion Medicine and a postdoctoral research fellowship, at Washington University in St. Louis.

As the principle of Advanced Cell & Gene Therapy, a consulting firm specializing in cell, gene, and tissue-based therapies, Dr. Burger works with clients in industry and academic centers worldwide. He provides assistance in process development and validation, GMP/GTP manufacturing, GMP facility design and operation, regulatory affairs, technology evaluation, and strategic analysis.

Dr. Burger is on the USP Cell, Gene and Tissue Therapies Expert Committee, and the advisory boards of several cell therapy biotechnology companies. He has served as editor of the International Society for Cellular Therapy Telegraft, and on the ISCT Executive Committee. He is a past medical director of the Cell Therapy Clinical Laboratory and Molecular and Cellular Therapeutics Facility at University of Minnesota, where he was responsible for process development, validation, and GMP production of a broad range of novel cell and gene therapies, in support of over 75 clinical trials. Dr. Burger also was Vice-President for Research and Development at Merix Bioscience, a biotechnology company focused on dendritic cell immunotherapy. He is a frequently invited speaker at industry and academic conferences and is the author of over 100 scientific publications and presentations, and recipient of numerous honors and awards.

4. Gary C. du Moulin, PhD, MPH, MS

Gary C. du Moulin is the Senior Director of Quality Compliance for Genzyme Biosurgery. After completing his BS in 1969 from the Military College of Vermont-

Norwich University and an MS degree from Northeastern University, Dr. du Moulin received a MPH and PhD degrees from Boston University.

Dr. du Moulin oversees the development and execution of robust quality systems for cell therapy and tissue engineered products at Genzyme. He currently serves on the Gene Therapy, Cell Therapy, and Tissue Engineering Expert Committee of the United States Pharmacopoeia and chairs the *ad hoc* advisory panel for fetal bovine serum.

Dr. du Moulin joined Genzyme in 1995 after working for six years developing quality systems for cellular therapies for the treatment of renal cell carcinoma. Prior to Dr. du Moulin's industrial experience, he spent 15 years in the Department of Anaesthesia at Harvard Medical School (Beth Israel Hospital) in Boston. He serves on the editorial board of *Regenerative Medicine* and is the past Chairman of the Editorial Board of the Regulatory Affairs Professionals Society Magazine, *RAPS Focus*. He has more than 150 publications in the areas of microbiology, epidemiology, and the regulation and quality control of living cells as a therapeutic modality. He is retired from the U.S. Army Reserve at the rank of Colonel after 38 years of service.

5. Theodora Ross, MD, PhD

Dr. Theodora Ross is an Associate Professor of Internal Medicine and the Associate Director of the Medical Scientist Training Program at the University of Michigan. After completing her BA at Kalamazoo College (music and biology), she earned her PhD and MD at Washington University and completed a residency in Medicine at Brigham and Women's Hospital and a Clinical Oncology fellowship and Postdoctoral Fellowship at the Dana-Farber Cancer Institute.

Dr. Ross' research focuses on mechanisms that transform normal cells into cancer cells, particularly on the Huntingtin Interacting Protein 1 (HIP1) family. Her research has been recognized by a number of awards including receipt of the American Society of Hematology Scholar Award, the Damon Runyon Scholar Award, the Jerome W. Conn Research Award from the University of Michigan, the Leukemia and Lymphoma Society Scholar Award, and a Burroughs Wellcome Fund Clinical Scientist Award.

Dr. Ross is certified by the American Board of Internal Medicine and the American Board of Internal Medicine, Oncology and has an active breast cancer clinic in the University of Michigan Cancer Center. She has served as a manuscript reviewer including the New England Journal of Medicine and the Proceedings of the National Academy of Sciences and has served on several DOD breast and ovarian cancer research program study sections. Dr. Ross was elected as a fellow of the American Society for Clinical Investigation in 2004. She has been the principal investigator on several grants funded by the National Institutes of Health, the Burroughs Wellcome Fund, Damon Runyon Foundation and the Department of Defense and numerous other foundations and societies.